Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
CPhI North AmericaCPhI North America
Not Confirmed
Not Confirmed
02-04 June, 2026
Not Confirmed
Not Confirmed
03-05 June, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
CPhI North AmericaCPhI North America
Industry Trade Show
Not Confirmed
02-04 June, 2026
Industry Trade Show
Not Confirmed
03-05 June, 2026
Digital content
NEWS #PharmaBuzz
05 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sebela-pharmaceuticals-presents-phase-3-tegoprazan-data-in-erosive-esophagitis-at-digestive-disease-week-ddw-2026-302762622.html
23 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sebela-pharmaceuticals-announces-positive-topline-results-from-phase-3-triumph-program-of-tegoprazan-in-gerd-302435337.html
04 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/04/3020323/0/en/Microbot-Medical-Announces-Late-Breaking-Abstract-Acceptance-at-the-Society-of-Interventional-Radiology-Annual-Meeting.html
30 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/30/3002679/0/en/Microbot-Medical-Concludes-2024-by-Achieving-Key-Milestones-Culminating-in-FDA-Submission-for-the-Commercialization-of-LIBERTY.html
05 May 2017
// PRESS RELEASE
http://www.patentdocs.org/2017/05/braintree-laboratories-inc-v-breckenridge-pharmaceutical-inc-fed-cir-2017.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+PatentDocs+%28Patent+Docs%29
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Click Us!
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42368
Submission : 2025-10-06
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42368
Submission : 2025-10-06
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.
Lead Product(s): Tegoprazan
Therapeutic Area: Gastroenterology Brand Name: K-CAB
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: HK inno.N
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 08, 2025
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : HK inno.N
Deal Size : Inapplicable
Deal Type : Inapplicable
HK inno.N’s Novel Drug K-CAB Succeeds in U.S. Phase 3 Trial Moving Toward FDA Submission
Details : K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.
Product Name : K-CAB
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2025
Details:
K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.
Lead Product(s): Tegoprazan
Therapeutic Area: Gastroenterology Brand Name: K-CAB
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 07, 2025
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sebela Completes Phase 3 TRIUMpH Trial of Tegoprazan in GERD
Details : K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.
Product Name : K-CAB
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 07, 2025
Details:
BLI5100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Erosive Reflux Disease.
Lead Product(s): BLI5100
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 05, 2023
Lead Product(s) : BLI5100
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLI5100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Erosive Reflux Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 05, 2023
Details:
BLI5100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Erosive Reflux Disease.
Lead Product(s): BLI5100
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2022
Lead Product(s) : BLI5100
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease
Details : BLI5100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Non-Erosive Reflux Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2022
Details:
BLI5100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Esophagitis.
Lead Product(s): BLI5100
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2022
Lead Product(s) : BLI5100
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients with Erosive Esophagitis
Details : BLI5100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Esophagitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2022
Details:
K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.
Lead Product(s): Tegoprazan
Therapeutic Area: Gastroenterology Brand Name: K-CAB
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: HK inno.N
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2022
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : HK inno.N
Deal Size : Inapplicable
Deal Type : Inapplicable
K-CAB Enters Phase 3 Clinical Trials in US
Details : K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.
Product Name : K-CAB
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2022
Details:
Tegoprazan (CJ-12420) is a novel agent in development for the treatment of acid-related gastrointestinal diseases. Tegoprazan has already received marketing authorization in multiple territories, including South Korea and China.
Lead Product(s): Tegoprazan
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Sebela Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 19, 2022
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sebela Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegopraz...
Details : Tegoprazan (CJ-12420) is a novel agent in development for the treatment of acid-related gastrointestinal diseases. Tegoprazan has already received marketing authorization in multiple territories, including South Korea and China.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 19, 2022
Details:
This drug candidate is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Lead Product(s): Undisclosed
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 24, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study 301: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy
Details : This drug candidate is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 24, 2020
Details:
This drug candidate is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Lead Product(s): Undisclosed
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 24, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy
Details : This drug candidate is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 24, 2020
Details:
BLI800 is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): BLI800
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 02, 2020
Lead Product(s) : BLI800
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label Preference Evaluation of BLI800
Details : BLI800 is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : USA
BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
Dosage Form : FOR SOLUTION, TABLET, DE...
Brand Name : HALFLYTELY
Dosage Strength : 5MG,N/A;N/A,210GM;N/A,...
Packaging :
Approval Date :
Application Number : 21551
Regulatory Info :
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
Dosage Form : FOR SOLUTION, TABLET, DE...
Brand Name : HALFLYTELY
Dosage Strength : 5MG,N/A;N/A,210GM;N/A,...
Packaging :
Approval Date : 2010-07-16
Application Number : 21551
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Dosage Form : FOR SOLUTION;ORAL
Brand Name : PIZENSY
Dosage Strength : 10GM
Packaging :
Approval Date : 2020-02-12
Application Number : 211281
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : USA
Dosage Form : SOLUTION;ORAL
Brand Name : PIZENSY
Dosage Strength : 20G
Packaging :
Approval Date :
Application Number : 211281
Regulatory Info :
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
Dosage Form : SOLUTION;ORAL
Brand Name : SUCLEAR
Dosage Strength : 1.6GM/BOT,3.13GM/BOT,1...
Packaging :
Approval Date : 2013-01-18
Application Number : 203595
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Dosage Form : SOLUTION;ORAL
Brand Name : AXID
Dosage Strength : 15MG/ML **Federal Regi...
Packaging :
Approval Date : 2004-05-25
Application Number : 21494
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : USA
Dosage Form : FOR SOLUTION; ORAL
Brand Name : MIRALAX
Dosage Strength : 17GM/SCOOPFUL
Packaging :
Approval Date :
Application Number : 20698
Regulatory Info :
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Inspections and registrations
ABOUT THIS PAGE
BRAINTREE LABS is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find Tegoprazan bulk with DMF offered by BRAINTREE LABS
Share 
